🔥🐔 BizChicken 🐔🔥

Companies Similar to Nkarta, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

AGENT-797

Mi NK Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases.

Tags: AGENT-797, biopharmaceutical, cancer, cell therapy, immune-mediated diseases

Symbol: INKT

Recent Price: $0.63

Industry: Biotechnology

CEO: Dr. Jennifer S. Buell Ph.D.

Sector: Healthcare

Employees: 31

Address: 149 Fifth Avenue, New York, NY 10010

Phone: 212 994 8250

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

KZR-616

Kezar Life Sciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer in the United States.

Tags: biotechnology, cancer, clinical trials, immune-mediated diseases, immunoproteasome inhibitor, small molecule therapeutics

Symbol: KZR

Recent Price: $6.82

Industry: Biotechnology

CEO: Dr. Christopher J. Kirk Ph.D.

Sector: Healthcare

Employees: 58

Address: 4000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 822 5600

Leadership

  • Christopher Kirk, PhD, Chief Executive Officer, Co-Founder
  • Marc Belsky, Chief Financial Officer
  • Mark Schiller, Chief Legal Officer
  • Neel K. Anand, DPhil, SVP, Research and Drug Discovery
  • Zung To, SVP, Clinical Development
  • Gitanjali Jain, SVP, Investor Relations and External Affairs
  • Michelle Greenman, VP, Global Regulatory Affairs
  • Jim Kirchner, PhD, VP, CMC and Supply Chain
  • Andrew Basham, VP, Legal Affairs
  • Dave Braggs, VP, Quality Assurance
  • Pattie Chiang, SVP, Corporate Controller
  • Tony Muchamuel, VP, Pharmacology & Toxicology
  • Kiruthi Palaniswamy, PharmD, VP, Medical Affairs
  • Mary Rogers, VP, Financial Planning & Analysis
  • Joe Tedrick, VP, Human Resources
  • Jinhai Wang, PhD, VP, Drug Metabolism & Pharmacokinetics
  • John Fowler, Co-Founder
  • Graham Cooper, Board Member, Beam Therapeutics, Former CFO, Receptos
  • Franklin Berger, Founder
  • Elizabeth Garner, MD, MPH, Chief Science Officer
  • Michael Kauffman, MD, PhD, President, Chief Executive Officer, and Director
  • Micki Klearman, MD, Former Group Medical Director
  • Courtney Wallace, Venture Partner

Last updated: 2024-12-31

NexImmune, Inc.

NexImmune, Inc. logo
Market Cap: Lowest
Employees: Lowest

Artificial Immune Modulation

Nex Immune, Inc., a clinical-stage biotechnology company, develops therapies for cancer and immune-mediated diseases using its Artificial Immune Modulation platform. The company is advancing cell therapy candidates including NEXI-001, NEXI-002, and NEXI-003.

Tags: T cell immunotherapies, biotechnology, cancer, cell therapy, immune-mediated diseases, nanoparticle technology

Symbol: NEXI

Recent Price: $0.15

Industry: Biotechnology

CEO: Mr. John Trainer M.B.A.

Sector: Healthcare

Employees: 6

Address: 9119 Gaither Road, Gaithersburg, MD 20877

Phone: 301 825 9810

Leadership

  • Kristi Jones, Chief Executive Officer
  • Mathias Oelke, Ph.D., Chief Scientific Officer
  • Daniel Bednarik Ph.D., Senior Vice President, Molecular Engineering & Protein Design
  • Jack Ragheb, Senior Vice President, Translational Science
  • Tonya Catterton, Vice President, Quality & Compliance
  • Tim Stover, Vice President, Corporate Controller
  • Karen Haslbeck, Head, Human Resources
  • Matt Schiller, Head, Business Development

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Vaxart, Inc.

Vaxart, Inc. logo
Market Cap: Low
Employees: Low

Oral Recombinant Protein Vaccines

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines using a proprietary oral vaccine platform. Their product pipeline includes vaccines for norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus, along with therapeutic vaccines for cervical cancer and dysplasia.

Tags: HPV, RSV, biotechnology, cervical cancer, coronavirus, influenza, norovirus, oral vaccines

Symbol: VXRT

Recent Price: $0.69

Industry: Biotechnology

CEO: Mr. Steven Lo

Sector: Healthcare

Employees: 109

Address: 170 Harbor Way, South San Francisco, CA 94080

Phone: 650 550 3500

Last updated: 2024-12-31

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

XCART

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.

Tags: CAR T, biopharmaceutical, biotechnology, drug delivery, oncology, therapeutics

Symbol: XBIO

Recent Price: $4.05

Industry: Biotechnology

CEO: Mr. James F. Parslow

Sector: Healthcare

Employees: 4

Address: 40 Speen Street, Framingham, MA 01701

Phone: 781 778 7720

Leadership

  • James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
  • Scott N. Cullison, Business Development
  • Reid P. Bissonnette, Ph.D., Translational Research and Development
  • Cory C. Kauffman, Ph.D., Chief Technology Officer
  • Adam Logal, Chairman
  • Grigory G. Borisenko, Ph.D., Non-Executive Director
  • James Eric Callaway, Ph.D., Non-Executive Director
  • Firdaus Jal Dastoor, FCS, Non-Executive Director
  • Dmitry Genkin, MD, Non-Executive Director
  • Roger Kornberg, Ph.D., Non-Executive Director
  • Moshe Mizrahy, Non-Executive Director
  • Dr. Alexey Vinogradov, Non-Executive Director

Last updated: 2024-12-31

Nektar Therapeutics

Nektar Therapeutics logo
Market Cap: Low
Employees: Low

Bempegaldesleukin

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs. Their products include Bempegaldesleukin, an IL-2 pathway agonist in clinical trials for various cancers and COVID-19, and NKTR-358, a cytokine Treg stimulant for autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, medicines, oncology

Symbol: NKTR

Recent Price: $0.94

Industry: Biotechnology

CEO: Mr. Howard W. Robin

Sector: Healthcare

Employees: 137

Address: 455 Mission Bay Boulevard South, San Francisco, CA 94158

Phone: 415 482 5300

Leadership

  • Howard W. Robin, President & Chief Executive Officer
  • Robert Bacci, Senior Vice President, HR and Facilities Operations
  • Sandra Gardiner, Chief Financial Officer
  • Jennifer Ruddock, Chief Business Officer
  • Mary Tagliaferri, M.D., Chief Medical Officer
  • Mark A. Wilson, Chief Legal Officer
  • Jonathan Zalevsky, Ph.D., Chief Research & Development Officer

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31